TrialsgrambetaRCTs are beautiful

DECLARE-TIMI 58

2019

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

In 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.

Result

Efficacy: CV death/HF hospitalisation and MACE (co-primary)HR 0.83

Below 1 favours dapagliflozin, above 1 favours placebo.

Also reported: MACE not significantly reduced.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Wiviott SD, et al. N Engl J Med. 2019;380(4):347-357.doi 10.1056/NEJMoa1812389

Discussion & critique

The largest SGLT2i outcomes trial, with the most primary-prevention patients: benefit was mainly heart-failure prevention rather than atherothrombotic events.

Discussed in podcasts